RT Journal Article
SR Electronic
T1 Statistical Assessment of Biomarker Replicability using MAJAR Method
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.08.22283210
DO 10.1101/2022.12.08.22283210
A1 Xie, Yuhan
A1 Zhai, Song
A1 Jiang, Wei
A1 Zhao, Hongyu
A1 Mehrotra, Devan V.
A1 Shen, Judong
YR 2022
UL http://medrxiv.org/content/early/2022/12/09/2022.12.08.22283210.abstract
AB In the era of precision medicine, many biomarkers have been discovered to be associated with drug efficacy and safety responses, which can be used for patient stratification and drug response prediction. Due to small sample size and limited power of randomized clinical studies, meta-analysis is usually conducted to aggregate all available studies to maximize the power for identifying prognostic and predictive biomarkers. Since all available data are already aggregated, it is often challenging to find an independent study to replicate the discoveries from the meta-analysis (e.g., in meta-analysis of pharmacogenomics genome-wide association studies (PGx GWAS)), which seriously limits the potential impacts of the discovered biomarkers. To overcome this challenge, we develop a novel statistical framework, MAJAR (Meta-Analysis of Joint effect Associations for biomarker Replicability assessment), to jointly test prognostic and predictive effects and assess the replicability of identified biomarkers by implementing an enhanced Expectation–Maximization algorithm and calculating their posterior-probability-of-replicabilities (PPR) and Bayesian false discovery rates (Fdr). Extensive simulation studies were conducted to compare the performance of MAJAR and existing methods in terms of Fdr, power, and computational efficiency. The simulation results showed improved statistical power with well-controlled Fdr of MAJAR over existing methods and robustness to outliers under different data generation processes while considering both prognostic and predictive effects in the model. We further demonstrated the advantages of MAJAR over existing methods by applying MAJAR to the PGx GWAS summary statistics data from a large cardiovascular randomized clinical trial (IMPROVE-IT). Compared to testing main effects only, MAJAR identified 12 novel variants associated with the treatment-related LDL cholesterol (LDL-C) reduction from baseline.Competing Interest StatementS.Z., D.V.M. and J.S. are employees at Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. The remaining authors declare no competing interests.Clinical TrialNCT00202878Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This manuscript is mainly a methodology paper. The research has no procedure related to collecting human subject data. The IMPROVE-IT data or summary statistics data were obtained after a request.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenotype data were processed using PLINK v2.00: https://www.cog-genomics.org/plink/1.9/; MAMBA R package: https://github.com/dan11mcguire/mamba; metafor R package v3.4.0: https://cran.r-project.org/package=metafor; Rcpp R package v1.0.9: https://cran.r-project.org/package=Rcpp; TMB R package v1.9.1: https://cran.r-project.org/package=TMB; figures were generated using ggplot2 R package v3.3.6: https://cran.r-project.org/package=ggplot2 and figures with break axis were generated using ggbreak package v0.1.1: https://cran.r-project.org/package=ggbreak; Manhattan plot was generated using qqman R package v0.1.8: https://cran.r-project.org/package=qqman; Venn diagram was generated using ggvenn R package v0.1.9: https://cran.r-project.org/package=ggvenn; upset plot was generated using UpSetR R package v1.4.0; GWAS Catalog: https://www.ebi.ac.uk/gwas; Open Targets: https://www.opentargets.org. Our method is implemented in the MAJAR R package, freely available at https://github.com/JustinaXie/MAJAR.